

Special Issue

Development of Vaccines against Zika Virus

Message from the Guest Editors

Zika virus (ZIKV) is a neurotropic, mosquito-transmitted flavivirus, which recently, and alarmingly, has been demonstrated to be transmitted by sexual and transplacental routes. Of relevance is the transplacental route of infection because of its association with the development of microcephaly and other severe birth defects in babies born to ZIKV infected mothers. Currently, there are no approved vaccines or therapies to combat ZIKV infection. Immune-based therapies have historically been successful in controlling a number of viral infections. Therefore, development of new vaccines and therapies that can confer immunity and/or treat clinical symptoms of ZIKV is greatly desired. I hope that you will agree to share your expertise in this area by writing a review article for our Special Issue. The journal will follow up with instructions and other logistics for your review.

Keywords: Zika virus; Flaviviruses; Vaccines; Animal models; Immune responses

Guest Editors

Prof. Kar Muthumani

1. Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
2. GeneOne Life Science Inc., Fort Washington, PA 19034, USA

Dr. David A. Schwartz

Perinatal Pathology Consulting, Atlanta, GA, USA

Dr. Gary Kobinger

1. Centre de Recherche en Infectiologie, Université Laval, Québec, QC, Canada
2. Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
3. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Deadline for manuscript submissions

closed (31 August 2018)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/14377

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).